Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.57 |
| ▸ | PPARG | P37231 | 6/20 | 0.54 |
| ▸ | PPARA | Q07869 | 6/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL607372 | 1.00 | CYP1A2 (0.65) | CYP1A2CYP2C9CYP2C19GAAPKM | |
| SCHEMBL117259 | 1.00 | CYP1A2 (0.65) | CYP1A2CYP2C9CYP2C19GAAPKM | |
| Ammonia Solution, Strong SCHEMBL28260028 | 0.98 | CYP1A2 (0.62) | CYP1A2CYP2C9CYP2C19GAAPKM | |
| SCHEMBL20591019 | 0.98 | CYP1A2 (0.62) | CYP1A2CYP2C9CYP2C19GAAPKM | |
| SCHEMBL27765434 | 0.98 | CYP1A2 (0.62) | CYP1A2CYP2C9CYP2C19GAAPKM | |
| Hydrochloric Acid SCHEMBL11632943 | 0.98 | CYP1A2 (0.62) | CYP1A2CYP2C9CYP2C19GAAPKM | |
| SCHEMBL3217144 | 0.94 | CYP1A2 (0.59) | CYP1A2CYP2C9CYP2C19GAAPKM | |
| SCHEMBL135587 | 0.94 | CYP1A2 (0.59) | CYP1A2CYP2C9CYP2C19GAAPKM | |
| Dimethylamine SCHEMBL28509130 | 0.94 | EPHX2 (0.60) | CYP1A2CYP2C9CYP2C19GAAPKM | |
| Isopropylamine SCHEMBL27635387 | 0.94 | CYP1A2 (0.59) | CYP1A2CYP2C9CYP2C19GAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3723745-A1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD Pharma A/S (DK) | 2020-10-21 | — | — | EP | claimed |
| CN-111587109-A | Phenoxy acids for the treatment of neuromuscular disorders | NMD制药股份公司 | 2020-08-25 | — | — | CN | claimed |
| WO-2019115777-A1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | WO | claimed |
| US-20190183833-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS | 2019-06-20 | — | — | US | claimed |
| US-20190183834-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | claimed |
| EP-1971222-A2 | REDUCED SWEETNESS CONFECTIONARY COMPOSITIONS AND COATED/FILLED FOOD PRODUCTS | GENERAL MILLS, INC. (US) | 2008-09-24 | — | — | EP | claimed |
| WO-2007059066-A2 | REDUCED SWEETNESS CONFECTIONARY COMPOSITIONS AND COATED/FILLED FOOD PRODUCTS | GENERAL MILLS, INC. (US) | 2007-05-24 | — | — | WO | claimed |
| US-20070110844-A1 | REDUCED SWEETNESS CONFECTIONARY COMPOSITIONS AND COATED/FILLED FOOD PRODUCTS | GENERAL MILLS, INC. | 2007-05-17 | — | — | US | claimed |
| EP-1576194-B1 | BACTERIAL STRAINS OF DELFTIA ACIDOVORANS MC1-R, THEIR PRODUCTION AND THEIR USE IN THE PRODUCTION OF THE R ENANTIOMERS OF 2-PHENOXYPROPIONIC ACID DERIVATIVES | UFZ LEIPZIGHALLE GMBH (DE) | 2006-05-31 | — | — | EP | claimed |
| EP-1576147-B1 | BACTERIAL STRAINS DELFTIA ACIDOVORANS MC1-S, PRODUCTION AND USE THEREOF FOR THE PRODUCTION OF THE S ENANTIOMERS OF 2-PHENOXYPROPIONIC ACID DERIVATIVES | UFZ LEIPZIGHALLE GMBH (DE) | 2006-05-24 | — | — | EP | claimed |
| EP-0159864-B1 | METHOD OF MODIFYING TASTE | TATE & LYLE PUBLIC LIMITED COMPANY (GB) | 1989-07-19 | — | — | EP | claimed |
| EP-3986873-B9 | 5-[(1S)-1-(4-BROMOPHENOXY)ETHYL]-2H-TETRAZOLE DERIVATIVES AND RELATED COMPOUNDS AS CLC-1 ION CHANNEL INHIBITORS FOR TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2024-05-29 | — | — | EP | disclosed |
| EP-3986873-B1 | 5-[(1S)-1-(4-BROMOPHENOXY)ETHYL]-2H-TETRAZOLE DERIVATIVES AND RELATED COMPOUNDS AS CLC-1 ION CHANNEL INHIBITORS FOR TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2023-11-15 | — | — | EP | disclosed |
| EP-3986873-B1 | 5-[(1S)-1-(4-BROMOPHENOXY)ETHYL]-2H-TETRAZOLE DERIVATIVES AND RELATED COMPOUNDS AS CLC-1 ION CHANNEL INHIBITORS FOR TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2023-11-15 | — | — | EP | disclosed |
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| EP-0159864-B1 | METHOD OF MODIFYING TASTE | TATE & LYLE PUBLIC LIMITED COMPANY (GB) | 1989-07-19 | — | — | EP | disclosed |
| US-4803301-A | Process for producing optically active 2-phenoxypropionic acid | KIRIN BEER KABUSHIKI KAISHA (JP) | 1989-02-07 | — | — | US | disclosed |
| US-4800162-A | ENZYME-ACTIVATED MEMBRANE | SEPRACOR, INC. (US) | 1989-01-24 | — | — | US | disclosed |
| WO-1988007582-A1 | METHOD FOR RESOLUTION OF STEREOISOMERS IN MULTIPHASE AND EXTRACTIVE MEMBRANE REACTORS | SEPRACOR, INC. (US) | 1988-10-06 | — | — | WO | disclosed |
| EP-0159864-A2 | Method of modifying taste | TATE & LYLE PUBLIC LIMITED COMPANY (GB) | 1985-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | CYP1A2 4681/4885CYP2C9 4788/4885CYP2C19 4866/4885 |
| US-20190183834-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | CYP1A2 4681/4885CYP2C9 4788/4885CYP2C19 4866/4885 |
| US-20190183833-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | CYP1A2 4681/4885CYP2C9 4788/4885CYP2C19 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.